Alzheimer's disease mild cognitive impairment
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Clinical diagnosis of mild cognitive impairment due to Alzheimer's Disease - Abnormal CSF biomarker for aggregated amyloid - Signed informed consent for Amsterdam Dementia Cohort (ADC) (P2016.061) and Amsterdam Dementia Biobank (P2017.315) - Age >=50 years
Exclusion criteria
Exclusion criteria: - No CSF collection or MRI-imaging at screening at memory clinic - Clinical diagnosis of dementia or subjective cognitive decline - Other neurological diagnosis, such as Parkinson*s disease, symptomatic stroke, mental retardation, brain tumor or infection, likely to be cause of cognitive impairment - Major psychiatric disorder, such as psychosis, schizophrenia, depression with vital signs, severe personality disorder, abuse of alcohol or other substances, likely to be cause of cognitive impairment - Use of (oral) anticoagulants or other contraindications for lumbar puncture - Contraindications for MRI scan (e.g., metal implants, pacemaker)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main predictor: baseline and longitudinal biological processes measured with CSF proteomics. Main endpoints: decline in brain network measures over time compared to baseline. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints: - Decline in cognitive functioning over time compared to baseline as measured with a neuropsychological test battery - Progression to dementia | — |
Countries
Netherlands
Outcome results
None listed